Gilead Sciences is trading at ARS 73,375.00, up 4.60%, with biotech-sector strength.

  • The biotech index rose about 2.1% during the November 4 session, and Gilead gained alongside the rally.
  • On November 4, Gilead announced 23 planned presentations at December’s ASH meeting, including new pipeline and follow-up data. Available evidence does not establish the announcement as the direct cause of the share move.